Combined administration of quinidine and propafenone for atrial fibrillation: The CAQ-PAF study

Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2012, Pages 171-179

  O'Hara, Gilles E ^a,b   Philippon, François ^a,b   Gilbert, Marcel ^a,b   Champagne, Jean ^a,b   Michaud, Véronique ^c   Charbonneau, Lyne ^a   Pruneau, Guylaine ^d   Hamelin, Bettina A ^a   Geelen, Peter ^a   Turgeon, Jacques ^c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Centre Hospitalier de l'Amiante   (Canada)

Author keywords

antiarrhythmic agents; Atrial fibrillation; CYP2D6; propafenone

Indexed keywords

CYTOCHROME P450 2D6; PLACEBO; PROPAFENONE; QUINIDINE; ANTIARRHYTHMIC AGENT; CYTOCHROME P450 2D6 INHIBITOR;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSGEUSIA; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINUS RHYTHM; TREATMENT REFUSAL; AGED; ATRIAL FIBRILLATION; BLOOD; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEART RATE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPAFENONE; QUINIDINE;

EID: 84856611849     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011399574     Document Type: Article

References (49)

1. Page RL. Medical management of atrial fibrillation: Future directions. Heart Rhythm. 2007 ; 4 (3 suppl). S91-94
2. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006 ; 5: 1034-1049 (Pubitemid 44835130)
3. Chen LY, Shen WK. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm. 2007 ; 4 (3 suppl). S1-6
4. Levy S. Pharmacologic management of atrial fibrillation: current therapeutic strategies. Am Heart J. 2001 ; 141 (2 suppl). S15-21
5. Nemec J, Shen WK. Pharmacotherapy of atrial fibrillation. Expert Opin Pharmacother. 1999 ; 1: 81-96
6. Sra J, Dhala A, Blanck Z, Deshpande S, Cooley R, Akhtar M. Atrial fibrillation: epidemiology, mechanisms, and management. Curr Probl Cardiol. 2000 ; 25: 405-524
7. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001 ; 104: 292-296 (Pubitemid 32666950)
8. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003 ; 24: 1481-1487 (Pubitemid 37010577)
9. Dogan A, Ergene O, Nazli C, et al. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. Acta Cardiol. 2004 ; 59: 255-261 (Pubitemid 38796442)
10. Falk RH. Atrial fibrillation. N Engl J Med. 2001 ; 344: 1067-1078 (Pubitemid 32267978)
11. Kochiadakis GE, Marketou ME, Igoumenidis NE, et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing Clin Electrophysiol. 2000 ; 23 (11 pt 2). 1883-1887
12. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest. 2004 ; 125: 377-383 (Pubitemid 38223611)
13. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000 ; 342: 913-920 (Pubitemid 30177051)
14. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ; 347: 1825-1833 (Pubitemid 35417773)
15. Crijns HJ. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs. 2005 ; 65: 1651-1667 (Pubitemid 41138986)
16. Geelen P, O'Hara GE, Roy N, et al. Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery. Am J Cardiol. 1999 ; 84: 345 A348-347 A349
17. Bellandi F, Dabizzi RP, Cantini F, Natale MD, Niccoli L. Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation-a single-blind placebo-controlled study. Cardiovasc Drugs Ther. 1996 ; 10: 153-157
18. Dukes ID, Vaughan Williams EM. The multiple modes of action of propafenone. Eur Heart J. 1984 ; 5: 115-125 (Pubitemid 14161451)
19. Malfatto G, Zaza A, Forster M, Sodowick B, Danilo P, Rosen MR. Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J Pharmacol Exp Ther. 1988 ; 246: 419-426
20. McLeod AA, Stiles GL, Shand DG. Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther. 1984 ; 228: 461-466 (Pubitemid 14190757)
21. Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990 ; 322: 1764-1768 (Pubitemid 20194654)
22. Delpon E, Valenzuela C, Perez O, Casis O, Tamargo J. Propafenone preferentially blocks the rapidly activating component of delayed rectifier K+ current in guinea pig ventricular myocytes: voltage-independent and time-dependent block of the slowly activating component. Circ Res. 1995 ; 76: 223-235
23. Duan D, Fermini B, Nattel S. Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther. 1993 ; 264: 1113-1123 (Pubitemid 23318601)
24. Rolf S, Haverkamp W, Borggrefe M, et al. Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol. 2000 ; 362: 22-31 (Pubitemid 30431632)
25. Gross GJ, Castle NA. Propafenone inhibition of human atrial myocyte repolarizing currents. J Mol Cell Cardiol. 1998 ; 30: 783-793 (Pubitemid 28190722)
26. Fei L, Gill JS, McKenna WJ, Camm AJ. Effects of propafenone on calcium currents in single ventricular myocytes of guinea-pig. Br J Pharmacol. 1993 ; 109: 178-182 (Pubitemid 23113819)
27. Delgado C, Tamargo J, Henzel D, Lorente P. Effects of propafenone on calcium current in guinea-pig ventricular myocytes. Br J Pharmacol. 1993 ; 108: 721-727 (Pubitemid 23067943)
28. Deneer VH, Borgh MB, Kingma JH, Lie AHL, Brouwers JR. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci. 2004 ; 26: 66-78 (Pubitemid 38425436)
29. Chiladakis JA, Kalogeropoulos A, Patsouras N, Manolis AS. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol. 2004 ; 44: 859-863 (Pubitemid 39099586)
30. Hege HG, Hollmann M, Kaumeier S, Lietz H. The metabolic fate of 2H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet. 1984 ; 9: 41-55 (Pubitemid 14132431)
31. Funck-Brentano C, Kroemer HK, Lee JT, Roden DM. Propafenone. N Engl J Med. 1990 ; 322: 518-525
32. Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987 ; 75: 785-791 (Pubitemid 17052663)
33. Vozeh S, Haefeli W, Ha HR, Vlcek J, Follath F. Nonlinear kinetics of propafenone metabolites in healthy man. Eur J Clin Pharmacol. 1990 ; 38: 509-513 (Pubitemid 20181284)
34. Thompson KA, Iansmith DH, Siddoway LA, Woosley RL, Roden DM. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther. 1988 ; 244: 950-955 (Pubitemid 18090111)
35. Valenzuela C, Delgado C, Tamargo J. Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibers. J Cardiovasc Pharmacol. 1987 ; 10: 523-529
36. Haefeli WE, Vozeh S, Ha HR, Taeschner W, Follath F. Concentration-effect relations of 5-hydroxypropafenone in normal subjects. Am J Cardiol. 1991 ; 67: 1022-1026
37. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther. 1989 ; 45: 28-33 (Pubitemid 19047143)
38. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 ; 17: 102-105 (Pubitemid 10107632)
39. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996 ; 392: 30-34 (Pubitemid 26268326)
40. Funck-Brentano C, Kroemer HK, Pavlou H, Woosley RL, Roden DM. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol. 1989 ; 27: 435-444 (Pubitemid 19101150)
41. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther. 1989 ; 249: 134-142
42. Turgeon J, Pavlou HN, Wong W, Funck-Brentano C, Roden DM. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther. 1990 ; 255: 642-649
43. Turgeon J, Fiset C, Giguere R, et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J Pharmacol Exp Ther. 1991 ; 259: 789-798
44. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990 ; 336 (8714). 529-532 (Pubitemid 20278099)
45. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995 ; 5: 215-223
46. Evert B, Griese EU, Eichelbaum M. Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics. 1994 ; 4: 271-274
47. Reimold SC, Maisel WH, Antman EM. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol. 1998 ; 82 (8A). 66N - 71N
48. Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart. 2000 ; 84: 251-257
49. Lau CP, Chow MS, Tse HF, Tang MO, Fan C. Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. Am J Cardiol. 2000 ; 86: 1327-1332